• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Voyager Therapeutics Inc. (Amendment)

    2/14/24 4:19:07 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VYGR alert in real time by email
    SC 13G/A 1 d791499dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 5)*

     

     

    Voyager Therapeutics, Inc.

    (Name of Issuer)

    COMMON STOCK, $0.001 PAR VALUE PER SHARE

    (Title of Class of Securities)

    92915B106

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 92915B106    SCHEDULE 13G    Page 2 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures III, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    The percent of class was calculated based on 43,995,363 shares of common stock issued and outstanding as of October 30, 2023, as disclosed in the Issuer’s Prospectus Supplement filed with the Securities and Exchange Commission on November 6, 2023.


    CUSIP No. 92915B106    SCHEDULE 13G    Page 3 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures GP III, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 92915B106    SCHEDULE 13G    Page 4 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TRV GP III, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO


    CUSIP No. 92915B106    SCHEDULE 13G    Page 5 of 9 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Robert I. Tepper

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     186,423

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     186,423

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     186,423

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.4% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     IN

     


    CUSIP No. 92915B106    SCHEDULE 13G    Page 6 of 9 Pages

     

    Item 1.    Issuer  
       (a)   Name of Issuer:
         Voyager Therapeutics, Inc. (the “Issuer”)
       (b)   Address of Issuer’s Principal Executive Offices:
        

    75 Hayden Avenue

    Lexington, MA 02421

    Item 2.    Filing Person
       (a) – (c)   Name of Persons Filing; Address; Citizenship:
        

    (i) Third Rock Ventures III, L.P. (“TRV III”);

     

    (ii)  Third Rock Ventures GP III, L.P. (“TRV GP III”), which is the sole general partner of TRV III;

     

    (iii)  TRV GP III, LLC (“TRV GP III LLC”), which is the sole general partner of TRV GP III; and

     

    (iv) Robert I. Tepper (“Tepper,” and collectively with TRV III, TRV GP III and TRV GP III LLC, the “Reporting Persons”), the managing member of TRV GP III LLC.

     

    The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 201 Brookline Ave, Suite 1401, Boston, MA 02215.

     

    Each of TRV III and TRV GP III is a Delaware limited partnership. TRV GP III LLC is a Delaware limited liability company. Tepper is a United States citizen.

       (d)   Title of Class of Securities:
         Common stock, $0.001 par value per share, (the “Common Stock”)
       (e)  

    CUSIP Number:

     

    92915B106

    Item 3.    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       (a)   ☐    Broker or dealer registered under Section 15 of the Act;
       (b)   ☐    Bank as defined in Section 3(a)(6) of the Act;
       (c)   ☐    Insurance company as defined in Section 3(a)(19) of the Act;
       (d)   ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
       (e)   ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
       (f)   ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
       (g)   ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
       (h)   ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
       (j)   ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
       (k)   ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
         If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    CUSIP No. 92915B106    SCHEDULE 13G    Page 7 of 9 Pages

     

    Item 4.    Ownership.
       (a) and (b)    Amount beneficially owned:
          (i)    TRV III directly owns 0 shares of Common Stock (the “Shares”), which represents 0% of the outstanding shares of Common Stock.
          (ii)    TRV GP III is the general partner of TRV III and may be deemed to beneficially own any shares of Common Stock held by TRV III (if any).
          (iii)    TRV GP III LLC is the general partner of TRV GP III and may be deemed to beneficially own any shares of Common Stock held by TRV III (if any).
          (iv)    As a managing member of TRV GP III LLC, Tepper may be deemed to beneficially own any shares of Common Stock held by TRV III (if any). Additionally, as of December 31, 2023, Tepper directly owns 186,423 shares of Common Stock, which represents approximately 0.4% of the outstanding shares of Common Stock.
       (c)    Number of shares as to which such person has:

     

         Number of Shares of Common Stock  
    Reporting Person    (i)      (ii)      (iii)      (iv)  

    TRV III

         0        0        0        0  

    TRV GP III

         0        0        0        0  

    TRV GP III LLC

         0        0        0        0  

    Tepper

         186,423        0        186,423        0  

     

    (i)

    Sole power to vote or direct the vote

    (ii)

    Shared power to vote or to direct the vote

    (iii)

    Sole power to dispose or to direct the disposition of

    (iv)

    Shared power to dispose or to direct the disposition of

    The percent of class was calculated based on 43,995,363 shares of common stock issued and outstanding as of October 30, 2023, as disclosed in the Issuer’s Prospectus Supplement filed with the Securities and Exchange Commission on November 6, 2023.

     

    Item 5.   

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6.   

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.


    CUSIP No. 92915B106    SCHEDULE 13G    Page 8 of 9 Pages

     

    Item 7.   

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

    Item 8.   

    Identification and Classification of Members of the Group.

     

    Not applicable.

    Item 9.   

    Notice of Dissolution of Group.

     

    Not applicable.

    Item 10.   

    Certification.

     

    Not applicable.


    CUSIP No. 92915B106    SCHEDULE 13G    Page 9 of 9 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    THIRD ROCK VENTURES III, L.P.
    By: THIRD ROCK VENTURES GP III, L.P.,
    General Partner
    By: TRV GP III, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    THIRD ROCK VENTURES GP III, L.P.
    By: TRV GP III, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    TRV GP III, LLC
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    ROBERT I. TEPPER

    /s/ Kevin Gillis, As attorney-in-fact

    Robert I. Tepper
    Get the next $VYGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VYGR

    DatePrice TargetRatingAnalyst
    1/10/2025Overweight
    Cantor Fitzgerald
    12/2/2024$12.00Buy
    Citigroup
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    10/16/2024$15.00Outperform
    Leerink Partners
    3/26/2024$22.00Buy
    Guggenheim
    3/19/2024$30.00Buy
    H.C. Wainwright
    3/7/2024$16.00Buy
    Citigroup
    1/2/2024$14.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $VYGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ferguson Toby sold $34,595 worth of shares (10,086 units at $3.43), decreasing direct ownership by 6% to 157,914 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      4/4/25 4:10:01 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Sandrock Alfred sold $37,336 worth of shares (10,885 units at $3.43), decreasing direct ownership by 2% to 430,931 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      4/4/25 4:08:51 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Carter Todd Alfred sold $14,079 worth of shares (3,305 units at $4.26) and was granted 46,000 shares, increasing direct ownership by 53% to 123,718 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      2/24/25 4:21:45 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Voyager Therapeutics Inc.

      10-Q - Voyager Therapeutics, Inc. (0001640266) (Filer)

      5/6/25 4:02:24 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)

      5/6/25 4:01:12 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Voyager Therapeutics Inc.

      DEFA14A - Voyager Therapeutics, Inc. (0001640266) (Filer)

      4/23/25 4:02:12 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Financials

    Live finance-specific insights

    See more

    $VYGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

      - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

      3/31/25 7:00:47 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

      3/11/25 4:01:00 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

      LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

      3/4/25 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Voyager Therapeutics

      Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight

      1/10/25 9:15:32 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on Voyager Therapeutics with a new price target

      Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $12.00

      12/2/24 7:04:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush resumed coverage on Voyager Therapeutics with a new price target

      Wedbush resumed coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $11.00 from $7.00 previously

      11/29/24 7:27:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 6:13:11 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 5:12:26 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      8/7/24 4:10:26 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

      - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

      3/31/25 7:00:47 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

      3/11/25 4:01:00 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

      LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

      3/4/25 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

      LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe

      6/13/24 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

      LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through

      3/13/24 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care